Eli Lilly (LLY) Q3 earnings report 2023


Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Cristina Arias | Cover | Getty Images

Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions.

Here’s what Eli Lilly reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Earnings per share: 10 cents per share adjusted vs. 13 cents loss per share expected
  • Revenue: $9.50 billion vs. $8.95 billion expected

For the quarter ended…

Source cnbc.com

0 0 votes
Article Rating

Goldman says Israel-Hamas war could majorly impact Europe’s economy

Previous article

Palantir (PLTR) Q3 earnings

Next article

You may also like

Notify of
Inline Feedbacks
View all comments

More in Earnings